Literature DB >> 26697185

Pulmonary vascular changes 22 years after single lung transplantation for pulmonary arterial hypertension: a case report with molecular and pathological analysis.

Yidan D Zhao1, Jenny Peng1, Elise Granton1, Kathleen Lin1, Catherine Lu1, Licun Wu1, Tiago Machuca1, Thomas K Waddell1, Shaf Keshavjee1, Marc de Perrot1.   

Abstract

This study was undertaken to characterize the molecular and pathological mechanisms of pulmonary vascular remodeling in a patient who developed chronic lung allograft dysfunction and recurrent pulmonary hypertension (PH) 22 years after undergoing a right single lung transplantation for pulmonary arterial hypertension (PAH). Histopathologic examination of the explanted lungs at the time of retransplantation showed characteristics of diffuse vascular remodeling combined with features of acute and chronic thromboemboli and evidence of bronchiolitis obliterans in the right lung allograft. In contrast, the native left lung demonstrated pulmonary arterial changes in keeping with PAH associated with disseminated pulmonary ossification. Real-time polymerase chain reaction and Western blot-performed on the first lung allograft, the native lung, and the new donor lung-demonstrated increased expression of apoptotic-related gene and protein levels in the lung allograft compared with the native PAH lung and the donor lung. Localization of cell apoptosis determined by triple immunostaining for caspase 3, CD31, and smooth muscle actin was positive in the pulmonary endothelial cells but not the smooth muscle cells of the lung allograft, while no positive staining was detected for cell death in the native PAH lung. The presence of PH in the lung allograft 22 years after transplantation was associated with upregulation of apoptotic markers and evidence of apoptotic endothelial cell death compared with the native lung and donor lung.

Entities:  

Keywords:  apoptosis; proliferation; pulmonary hypertension; reoccurrence

Year:  2015        PMID: 26697185      PMCID: PMC4671752          DOI: 10.1086/683692

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  13 in total

Review 1.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

Authors:  R M Tuder; B Groves; D B Badesch; N F Voelkel
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

Review 3.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

4.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection.

Authors:  C D Cool; D Kennedy; N F Voelkel; R M Tuder
Journal:  Hum Pathol       Date:  1997-04       Impact factor: 3.466

5.  Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension.

Authors:  M E Yeager; G R Halley; H A Golpon; N F Voelkel; R M Tuder
Journal:  Circ Res       Date:  2001-01-19       Impact factor: 17.367

6.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

7.  Protein kinase G-I deficiency induces pulmonary hypertension through Rho A/Rho kinase activation.

Authors:  Yidan D Zhao; Lei Cai; Muhammad K Mirza; Xiaojia Huang; Dave L Geenen; Franz Hofmann; Jason X-J Yuan; You-Yang Zhao
Journal:  Am J Pathol       Date:  2012-06       Impact factor: 4.307

8.  Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension.

Authors:  R M Tuder; Z Radisavljevic; K R Shroyer; J M Polak; N F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  1998-12       Impact factor: 21.405

9.  Pulmonary hypertension in patients with bronchiolitis obliterans syndrome listed for retransplantation.

Authors:  S D Nathan; O A Shlobin; S Ahmad; S D Barnett; N A Burton; M T Gladwin; R F Machado
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

10.  Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.

Authors:  Fares A Masri; Weiling Xu; Suzy A A Comhair; Kewal Asosingh; Michelle Koo; Amit Vasanji; Judith Drazba; Bela Anand-Apte; Serpil C Erzurum
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-05-25       Impact factor: 5.464

View more
  1 in total

1.  Baicalin attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2A receptor-induced SDF-1/CXCR4/PI3K/AKT signaling.

Authors:  Xiaoying Huang; Peiliang Wu; Feifei Huang; Min Xu; Mayun Chen; Kate Huang; Guo-Ping Li; Manhuan Xu; Dan Yao; Liangxing Wang
Journal:  J Biomed Sci       Date:  2017-08-03       Impact factor: 8.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.